Search
for
Sort by
Research 571–600 of 1000+
- 153 Effectiveness of OR-101, a next generation highly selective JAK3 inhibitor, in a humanized murine model of alopecia areata
- 27 Preclinical ex vivo and in vivo evidence supporting selective inhibition of tyrosine kinase 2-dependent, IL-12-mediated signaling as a novel pharmacological strategy for alopecia areata management
- Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- 84 Partial restoration of scalp microbiota in alopecia areata with JAK inhibitors
- 151 Efficacy and adverse effects of oral Janus kinase inhibitor (JAKi) use in patients with lichen planopilaris: a retrospective case series and systematic review
- Screening for latent infectious disease in patients with alopecia areata before initiating JAK inhibitors therapy: a single-center real-world retrospective study
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- 43647 Treatment of Refractory Folliculitis Decalvans with the Topical JAK Inhibitor Tofacitinib
- 44182 Treatment with Oral Janus Kinase Inhibitors in Adults Patients with Alopecia Areata: A Systematic Review and Meta-Analysis
- Efficacy of Janus kinase inhibitors in adult patients with alopecia areata
- Folliculitis Decalvans-like Alopecia During Treatment With EGFR Inhibitors for Lung Cancer: A Case Series of 6 Patients
- BH09 Patient experience of off-label Janus kinase inhibitor use for alopecia areata in a cohort of 34 patients from a single UK practitioner: exploring changing trends in healthcare provision and access to drug treatments
- Litigation associated with 5-alpha-reductase-inhibitor use: A Canadian legal database review.
- JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
- ISIDLB1777 - A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment
- 1332 Janus kinase inhibitor increases hair growth by increasing beta-catenin activity in outer root sheath cells
- 1339 Casein kinase 1 inhibition in keratinocytes enhances the migration of melanocyte precursors in the hair follicle via KitL/c-Kit signaling pathway
- 1367 Inhibition of the mitochondrial pyruvate carrier promotes ATF4–dependent stress responsive metabolic rewiring and cell cycle arrest in the human hair follicle
- 1112 An innovative phase 1b trial demonstrating proof-of-pharmacology for two novel IRAK4-inhibitors using a local (Imiquimod) and systemic (LPS) driven immune response
- Janus kinase inhibitor as a therapeutic option in alopecia areata. Case report
- Cepharanthine Inhibits Doxorubicin-Induced Cellular Senescence by Activating Autophagy via the mTOR Signaling Pathway
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
- 548 Deletion of Myelin Protein Zero-like 3 increases sebaceous gland size and sebocyte proliferation but reduces skin adipose depots: Can MPZL3 inhibition promote excessive loss of lipids via sebum hypersecretion?
- 557 Short-term Rho-associated kinase inhibitor treatment accelerates primary keratinocyte growth without affecting the characteristics of the stem cell population
- The Triumph of JAK Inhibitors for the Treatment of Alopecia Areata
- Alopecia Areata, triggered by psychological stress and successfully treated with a Janus kinase inhibitor. Case report
- 755 Repurposing of DPP4 inhibition to improve hair follicle activation and regeneration
- 700 Tyrosine kinase 2 inhibition rescues hair follicles from IL-12–mediated immune privilege collapse and reverses the induction of human alopecia areata in a humanized mouse model